Granted Patent B2

US 12,350,416 · App. 17/669,883 · Granted Jul 8, 2025

Inventors: Anthony DePasqua (Newburyport, MA); Kevin Eggan, Jr. (Boston, MA); Kevin Kalish (Newburyport, MA); Manual A. Navia (Lexington, MA); Kasper Roet (Somerville, MA); Ching-Hua Tseng (Belmont, MA); Alan D. Watson (Lexington, MA); William X. Siopes (Lowell, MA); Gianna N. Riccardi (South Berwick, ME); Marcie Ann Glicksman (Salem, MA)

Assignee: EnClear Therapies, Inc.

A61M1/3687A61M1/16A61M1/1601A61M27/006A61M1/3655A61M1/3659A61M2027/004A61M2202/0464A61M2205/103A61M2205/12A61M2205/3334A61M2205/3344A61M2205/3379A61M2210/1003A61M2210/1039

Abstract

Claims (32)

1. A method for treating a mammalian subject suffering from at least one of a pathology, trauma, a neurological disease, a non-neurological disease, or a deficiency characterized by presence of toxic biomolecules in a cerebrospinal fluid (CSF) by amelioration of the toxic biomolecules in the CSF using an ameliorating agent, an amelioration technique, or combinations thereof, the method comprising:

selecting a patient having at least one of a risk, a diagnosis, a prognosis, or at least one symptom of a condition selected from the group consisting of pathology, trauma, neurological disease, non-neurological disease, or deficiency;

removing a volume of CSF from a first location of the patient at a flow rate between about 0.1 mL/min and about 100 mL/min, the first location located at a lateral ventricle of the patient;

treating the removed volume of CSF;

returning the treated volume of CSF to the patient at a second location, the second location located at a lumbar sac of the patient; and

sensing measurable characteristics of the treated volume of CSF using one or more sensing devices as the treated volume of CSF is being returned to the patient, the measurable characteristics including an intracerebral pressure and an intrathecal pressure, wherein:

the intracerebral pressure at the first location ranges from about 5 mm Hg to about 15 mm Hg, the intrathecal pressure at the second location ranges from about 5 mm Hg to about 15 mm Hg;

using anti-backflow valves to control the flow of the CSF through one or more of the first location and the second location to substantially prevent backward fluid flow and to permit one or more of: priming, flushing, gas purging, or removal of occlusions; and

the intracerebral pressure and the intrathecal pressure are each maintained within the ranges of from about 5 mm Hg to about 15 mm Hg.

2. The method of claim 1 , wherein treating the removed volume of CSF comprises treating with a protease comprising a trypsin.

3. The method of claim 2 , wherein the protease is bound to a resin.

4. The method of claim 3 , where the resin comprises a porous resin.

5. The method of claim 3 wherein the resin comprises a porous bead that incorporates the protease.

6. The method of claim 3 , where the resin comprises methacrylate.

7. The method of claim 3 , where the resin comprises agarose.

8. The method of claim 1 , wherein the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), Alzheimer disease (AD), frontotemporal degeneration (FfD), progressive supranuclear palsy (PSP), Huntington disease (HD), Parkinson disease (PD), cancer, intracranial metastatic disease (IMD), diabetes, type-3 diabetes, lupus, poisoning, trauma, chronic traumatic encephalopathy (CTE), bacterial meningitis, aneurysms, stroke, cerebral vasospasms, and traumatic brain injury.

9. The method of claim 1 , wherein the neurological disease is ALS.

10. The method of claim 1 , wherein treating the removed volume of CSF comprises at least one of removing, reducing, altering, sequestering, digesting, neutralizing, and deactivating one or more substances selected from the group consisting of: tau, cis p-tau, Abeta, TDP-43, SODI, DPRs, neurofilaments, and alpha-synuclein.

11. The method of claim 1 , wherein the toxic biomolecules within the CSF includes TDP-43.

12. The method of claim 1 , further comprising using a CSF fluid loop with a first access port and a second access port to remove the volume of CSF from the first location at the first access port and return the treated volume of CSF via the second access port.

13. The method of claim 12 , wherein the CSF fluid loop comprises at least one sensor.

14. The method of claim 13 , further comprising providing at least one of a pump, a valve, or an actuator located within the CSF fluid loop.

15. The method of claim 14 , wherein the pump is selected from the group consisting of a peristaltic pump, a rotary vane pump, an Archimedes screw, an air bladder, a pneumatic bladder, a hydraulic bladder, a displacement pump, an electromotive pump, a passive pump, an autopump, a valveless pump, a bi-directional pump, and combinations thereof.

16. The method of claim 1 , further comprising:

measuring a fluid characteristic;

determining whether the measured fluid characteristic meets a prescribed relationship to a predetermined threshold for a period of time;

updating at least one parameter of a set of treatment operational parameters as a function of said determining, the operational parameters being updated to maintain at least one of a specific volume change, or a specific flow rate within a CSF space of the patient.

17. The method of claim 1 , wherein the ameliorating agent is a therapeutic substance.

18. The method of claim 17 , wherein the therapeutic substance is a drug that includes secreted molecules having trophic factors or anti-inflammatory molecules, or genetically engineered to produce trophic factors or anti-inflammatory molecules.

19. The method of claim 1 , wherein amelioration is performed by one or more of digestion, enzymatic digestion, filtration, size filtration, tangential flow filtering, countercurrent cascade ultrafiltration, centrifugation, separation, magnetic separation (including with nanoparticles and the like), electrophysical separation (performed by means of one or more of enzymes, antibodies, nanobodies, molecular imprinted polymers, ligand-receptor complexes, and other charge and/or bioaffinity interactions), photonic methods (including fluorescence-activated cell sorting (FACS), ultraviolet (UV) sterilization, and/or optical tweezers), photo-acoustical interactions, chemical treatments, thermal methods, and combinations thereof.

20. The method of claim 1 , wherein the ameliorating agent includes one or more of enzymes, antibodies or antibody fragments, nucleic acids, receptors, anti-bacterial, anti-viral, antiDNA/RNA, protein/amino acid, carbohydrate, enzymes, isomerases, compounds with highlow biospecific binding affinity, aptamers, exosomes, ultraviolet light, temperature change, electric field, molecular imprinted polymers, or living cells.

21. The method of claim 1 , wherein the ameliorating agent includes one or more of trypsin; elastase; clostripain; calpains, including calpain-2; caspases, including caspase-1, caspase-3, caspase-6, caspase-7, and caspase-8; M24 homologue; human airway trypsin-like peptidase; proteinase K; thermolysin; Asp-N endopeptidase; chymotrypsin; LysC; LysN; glutamyl endopeptidase; staphylococcal peptidase; arg-C proteinase; proline-endopeptidase; thrombin; cathepsin, including the cathepsins E, S, B, K, or Ll; Tissue Type A; heparinase; granzymes, including granzyme A; meprin alpha; pepsin; endothiapepsin; kallikrein-6; kallikrein-5; pinl; and exosomes.

Assignments (1)

Continuity (5)

References Cited (299)